CTRI/2021/03/032019尚未招募未知
Phase II study of the efficacy and safety of Posaconazole tablets as anti-fungal prophylaxis in patients undergoing chemotherapy and stem cell transplantation
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients diagnosed to have acute myeloid leukemia receiving intensive chemotherapy [7+3 induction, Salvage chemotherapy with FLAG/FLAG-Ida/5+5 chemotherapy] â?? Group 1
- •2.Patients who have developed acute GVHD after allogeneic HSCT and are initiated on corticosteroids at 1-2 mg/Kg/day â?? Group 2
- •3.Adults > 15 years of age
排除标准
- •1. Patients with AML receiving azacytidine/decitabine based chemotherapy
- •2. Patients following HSCT who are already on mold prophylaxis or amphotericin
- •3. Patients present with invasive fungal infection at diagnosis
- •4. Patients with > grade 3 hepatic dysfunction ie Total Billirubin > 3 mg% and/or
- •SGOT/SGPT > 200 IU/L
- •5.Patients where the expected life expectancy is less than 1 week
研究者
相似试验
已完成
不适用
Phase II study evaluating efficacy and safety of peripheral blood stem cell harvest with bortezomib for multiple myelomaMultiple MyelomaJPRN-UMIN000010258Fourth Department of Internal Medicine, Sapporo Medical University, School of Medicine30
已完成
3 期
A phase III study of the safety and efficacy of povidone-iodine nasal spray (Nasodine”) in the treatment of subjects with the common cold in the natural setting.Common ColdInfection - Other infectious diseasesACTRN12619000764134Firebrick Pharma Pty Ltd256
进行中（未招募）
不适用
Phase 2 Study of Posaconazole in Chagas DiseaseEUCTR2013-000161-36-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc.,160
已完成
2 期
Phase 2 study of efficacy and safety of fosaprepitant in patients with solid tumor receiving highly emetogenic chemotherapyPatients with solid tumor receiving highly emetogenic chemotherapy including cisplatin.JPRN-UMIN000012202Kyushu University40
进行中（未招募）
1 期
A phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failureRecurrent unresectable or metastatic cervix carcinomaMedDRA version: 21.1Level: PTClassification code 10008344Term: Cervix carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002184-97-FRCentre François Baclesse57